eFFECTOR Therapeutics, Inc. (EFTR) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is EFTR = $6 (+2749900% upside).
Net income is $36M (loss), growing at -115.9%/yr. Net profit margin is 0% (thin). Gross margin is 98.5% (+50.5 pp trend).
Balance sheet: total debt is $21M with negative equity of -$6M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.77 (tight liquidity). Debt-to-assets is 100%. Total assets: $21M.
Analyst outlook: 6 / 6 analysts rate EFTR as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 50/100 (Partial), Health 0/100 (Fail), Moat 50/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).
